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Abstract 
Multipurpose prevention technologies (MPTs) are preferably single dosage forms 
designed to simultaneously address multiple sexual and reproductive health needs, 
such as unintended pregnancy, HIV infection and other sexually transmitted 
infections (STIs).  This manuscript describes the development of a range of multi-
layered vaginal tablets, with both immediate and sustained release layers capable of 
delivering the antiretroviral drug dapivirine, the contraceptive hormone 
levonorgestrel, and the anti-herpes simplex virus drug acyclovir at independent 
release rates from a single dosage form.  Depending on the design of the tablet in 
relation to the type (immediate or sustained release) or number of layers, the dose of 
each drug could be individually controlled.  For example one tablet design was able 
to provide immediate release of all three drugs, while another tablet design was able 
to provide immediate release of both acyclovir and levonorgestrel, while providing 
sustained release of Dapivirnie for up to 8 hours.  A third tablet design was able to 
provide immediate release of both acyclovir and levonorgestrel, a large initial burst of 
Dapivirine, followed by sustained release of Dapivirine for up to 8 hours.    All of the 
tablets passed the test for friability with a percent friability of less than 1%.  The 
hardness of all tablet designs were between 115 and 153 Newtons, while their  drug 
content met the European Pharmacopeia 2.9.40 Uniformity of Dosage units 
acceptance value at level 1 and 2.  Finally, the accelerated stability of all three 
actives was significantly enhanced in comparison to a mixed drug control.    
  
1. Introduction 
Multipurpose prevention technologies (MPTs) are products, preferably single device 
products, administered via a single route, that are designed to simultaneously 
address multiple sexual and reproductive health needs, such as unintended 
pregnancy, HIV infection and other sexually transmitted infections (STIs) [1].  MPTs 
can fall into a number of categories: 1) a drug delivery device or formulation that 
releases multiple active agents of which each is effective against a different 
indication, 2) a drug delivery device or formulation that release a single active agent 
that is effective against a range of different indications or 3) a barrier device such as 
a condom or diaphragm in combination with one or more active agents which are 
effective against multiple indications. According to the Coalition Advancing 
Multipurpose Innovations (CAMI), every minute a woman is infected with HIV, there 
are 86 million unplanned pregnancies around the world annually and 1 million people 
contract an STI every day [2].  MPTs offer a solution to these overlapping 
reproductive health issues using a single device, which will result in a number of 
benefits for the users, including convenience, increased adherence, improved 
effectiveness, reduction in cost and environmental impact [3]. 
 
There are currently a number of MPT products on the market, such as the male and 
female condom and the cervical diaphragm.  The male condom is one of the key 
MPT barrier methods, which when used correctly is highly effective in protecting 
against pregnancy, HIV infection and many other common STIs [4-5]. However, 
inconsistent and improper use, as a result of poor acceptability, has resulted in 
failure rates, after one year of use, of approximately 15% and a pearl index of 15 [6], 
while many women cannot negotiate condom use with their partners [7]. The female 
  
condom is a female controlled barrier method, which has been shown to have a 
comparable or slightly higher contraceptive efficacy when compared to the male 
condom [8-9] and was just as effective in reducing the recurrence of bacterial STIs 
[10].  Although there is no actual data on HIV prevention, mathematical modelling 
has suggested an effectiveness of 63 to 82% [11-12].  However, the cost of the 
female condom is still higher than that of the male counterpart, with strategies, such 
as the washing, disinfecting and reusing of the female condom being employed to try 
and reduce its relative cost [13]. Cervical diaphragms are designed to sit on the 
cervix and are traditionally used for contraception and have a similar rate of 
effectiveness to the male condom [14].  The cervix has a high density of CD4 cells 
and CCR5 chemokine receptors and has been shown to be the initial site of infection 
for HIV and other STIs [15-17].  Therefore, diaphragms may offer protection from 
HIV and other STIs and thus act as an MPT, while  studies have shown that the 
incidences of gonorrhoea and chlamydia infections are lower in those women who 
use diaphragms over other barrier methods of contraception [18].  However, a large 
scale trial comparing the efficacy of using a diaphragm and a condom to condoms 
alone in preventing HIV-1, gonorrhoea and chlamydia in at-risk women 
demonstrated that there was no statistically significant difference between the two 
groups [19-20].  The Program for Appropriate Technology in Health (PATH) have 
developed a new ‘one size fits most’ SILCS diaphragm, which is manufactured from 
silicone and contains a polymer spring, rather than the metal spring used in most 
standard diaphragms.  The SILCS diaphragm performed well in Phase I post-coital 
barrier effectiveness testing.  However, it was recommended that for it to be most 
effective adjunctive use of a chemical barrier or spermicidal gel was needed [21].  
  
PATH, has investigated the development of a SILCS diaphragm that releases the 
HIV microbicide dapivirine [22]. 
Adherence and compliance issues are well understood in contraceptive and 
microbicide fields, with a recent Phase IIb study of a gel containing 1%w/w of the 
NRTI tenofovir lowering the risk of HIV infection in sexually active women by 54% 
provided they reported greater than 80% adherence, which fell to 38% protection if 
they had between 50% and 80% adherence and to 28% with less than 50% 
adherence [23]. This study clearly demonstrates the influence of adherence and 
compliance on the efficacy of a microbicide product and suggests that any future 
MPT products need to consider patient adherence to the required dosing regimen, 
particularly for those products which are coitally dependent. 
 
Solid dosage forms such as vaginal tablets may overcome some of the compliance, 
acceptability and adherence issues associated with other MPT strategies.  They are 
more discrete, easier to administer to the vagina and are coitally independent, 
especially when they are designed to be sustained release tablets.  A study in 
African women reported that 80% of the women tested liked using a vaginal tablet; 
while over 85% said they would definitely use them [24].  Sustained-release tablets 
are designed to slowly release drug at a rate governed predominately by the design 
of the delivery system.  Many sustained release formulations are specifically 
designed for once-daily per-oral administration and have been shown to improve 
patient compliance and acceptability compared with conventional multiple daily 
dosing regimens [25].  Multi-layered tablets are a flexible technology that has been 
used for modifying the release of drugs as well as delivering multiple drugs [26-29].  
Multi-layered tables have been used to achieve, zero order release [30-31], pulsatile 
  
release [32] and even bimodal release [33], were an initial immediate release phase 
is followed by a period of sustained release, and then a second immediate release 
phase.   Melt processing has be used to manufacture solid dosage forms for the 
purposes of solubility and bioavailability enhancement, through the productions of 
solid dispersions [34-37] and taste masking of bitter drugs [38-41]. 
 
This manuscript describes the development of a range of multi-layered vaginal 
tablets, with both immediate and sustained release layers capable of delivering the 
antiretroviral drug dapivirine, the contraceptive hormone levonorgestrel, and the anti-
herpes simplex virus drug acyclovir at independent release rates from a single 
dosage form, manufactured using a combination of melt processing and 
compression moulding.  
  
2. Materials and Methods 
2.1  Materials 
Dapivirine (DPV) was provided by the International Partnership for Microbicides, 
which holds exclusive rights to DPV through an agreement with Janssen Sciences 
Ireland UC, levonorgestrel (LNG) and acyclovir (ACY) were purchased from 
Cambridge Biosciences (Cambridge, UK).  Sodium dodecyl sulphate (SDS) and 
methanol were purchased from Sigma Aldrich (Dorset, England).  Kollidon® SR, 
Kollidon® VA Kolliphor® P 188 were provided by BASF (Ludwigshafen, Germany). 
2.2 Melt rheology  
Continuous flow rheological assessment of the formulations was carried out using a 
TA Instruments AR 2000 rotational rheometer fitted with a 40 mm diameter steel 
parallel plate. 3g of each formulation to be tested was placed onto the lower 
stationary plate of the rheometer, which was set to 200oC, and the upper plate was 
lowered to produce a gap between the plates of 1000 m.  Excess sample was 
removed before initiating the test. Flow rheology was conducted in temperature 
sweep mode with the temperature decreased to 120oC at a rate of 10oC per minute. 
2.3 Multi-layered tablet manufacture  
The appropriate amount of polymer (Kollidon® SR or Kollidon® VA), plasticizer 
(Kolliphor® P 188) and active (DPV, LNG or ACY) were blended together using a 
laboratory sized V-blender (SOCACHIM, Brussels, Belgium) to produce a 50g 
powder blend.  Multi-layered tablets were manufactured using combination of melt 
processing and compression moulding by placing the powder blend into the bottom 
portion of a 1mm deep mould that had been heated to either 160oC (Kollidon® SR 
  
blend) or 150oC (Kollidon® VA blend) depending on the blend being processed.  The 
blend was left in the mould for approximately 15 minutes (or until it was deemed soft 
enough to be compressed) and the top portion of the mould was pushed down until 
there was no gap between the bottom and top portions of the mould.  The top portion 
of the mould was removed and individual layers 14mm in diameter and 1mm thick 
were cut from the moulded powder blend.  The layers were subsequently butt 
welded together to form the multi-layered tablets presented in Figure 1. 
2.4 Content uniformity of the individual layers 
Each individual layer (n=4) was crushed using a mortar and pestle and the 
subsequent powder transferred to a 10mL volumetric flask.  The volumetric flask was 
made up to volume with 10mL of 2% SDS solution and placed onto a laboratory 
shaker overnight at 60 RPM.  A 1mL sample was removed, filtered and analysed 
using the dapivirine/acyclovir/levonorgestrel HPLC method.  The acceptance value 
was calculated as per Case 1 of the European Pharmacopeia 2.9.40 Uniformity of 
Dosage units. 
2.5 Determination of tablet hardness 
The mean hardness (n = 10) of the various tablets was measured with a tablet 
hardness tester (Varian VK 200).  Each tablet was placed in the hardness tester and 
the maximum force in Newton required to break each tablet was measured. 
2.6 Determination of tablet friability 
The friability of the tablets was determined by placing ten pre-weighed tablets, with a 
collective weight of approximately 3g for the three layered tablets and 4g for the four 
layered tablets, into the drum of a Charles Ischi AE-1 friability tester, which was 
  
subsequently rotated 50 times at a speed of 25 RPM. At the end of the test all ten 
tablets were dusted off and reweighed together, the loss in the weight of tablet is the 
measure of friability and is calculated using equation 1.  A friability of less than 1.0% 
is deemed a pass, if the tablets passed the first time the test was repeated using the 
same tablets.  However, if the friability was greater than 1.0%, then the tablets failed 
the test and were deemed unacceptable in relation to friability. 
Equation 1: Percentage Friability = W1 – W2/W1 × 100 
Where: W1 = collective weight of tablets before testing 
  W2 = collective weight of tablets after testing. 
2.7 In vitro drug release  
Individual multi-layered tablets (n = 4) were placed into a sealed flask containing 
10mL of 2% SDS and the flasks placed onto a laboratory shaker at 60 RPM in a 
walk-in incubator held at 37oC.  1mL samples were taken from the release medium 
and filtered after 0.25, 0.5, 1, 2, 4 and 8 hours and replaced with 1mL of fresh 
release medium.  DPV, ACY and LNG release was analysed using a 
dapivirine/acyclovir/levonorgestrel HPLC method.  
2.8 Forced degradation stability study 
Individual samples of DPV, ACY, LNG, a combination sample consisting of a 1:1:1 
ratio of DPV:ACY:LNG and the various multi-layered tablet formulations were placed 
in an incubator in open containers and stored at 80oC for 3 months to enhance 
degradation with samples removed after 1, 2 and 3 months.  The multi-layered 
tablets were crushed using a mortar and pestle and transferred to a 10mL volumetric 
flask while the individual samples and combination samples were transferred directly 
  
to the 10mL volumetric flask.  The volumetric flask was made up to volume with 
10mL of 2% SDS solution and placed onto a laboratory shaker overnight at 60 RPM.  
A 1mL sample was removed, filtered and analysed using the 
dapivirine/acyclovir/levonorgestrel HPLC method  
2.9 Dapivirine/Acyclovir/Levonorgestrel HPLC Methodology 
HPLC analysis was performed on a Waters Alliance HPLC with a Phenomenex 
Luna® C18 4.6 x 150 mm column with a 5M particle size.  A gradient flow was used 
as described in table 1 were mobile phase A was phosphate buffer and mobile 
phase B was HPLC grade acetonitrile.  The flow rate was 1.00mL/min, while UV 
detection was performed at a wavelength of 220nm with an injection volume of 20L.  
The limit of detection for the method is 0.001g/mL while the limit of quantification is 
0.01g/mL for all 3 actives.  The selectivity factor () between ACY and DPV was 
8.1 and DPV and LNG was 1.1.  The method was linear (r2 1.00) over the standard 
ranges used in this study, which was 0.01 to 500g/mL for ACY and DPV and 0.01 to 
5g/mL for LNG.  
2.10 Statistical analysis 
Statistical analysis was performed using a one way analysis of variance (ANOVA) 
(GraphPad Prism® version 5.02 for Windows, GraphPad Software, San Diego, CA).  
Post-hoc comparisons of the means were performed using Tukey’s Honestly 
Significance Difference test.  A significance level of p < 0.05 was accepted to denote 
significance in all cases.  
  
3. Results and Discussion 
3.1 Melt rheology 
The sustained release polymer Kollidon® SR was used to provide sustained release 
of DPV, while the immediate release polymer Kollidon® VA 64 was used to provide 
immediate release of DPV, ACY and LNG.  The multi-layered vaginal tablets were 
manufactured using melt compression moulding.  Therefore, it was necessary to 
determine the temperatures the sustained and immediate release polymers reached 
their optimum melt viscosity, which is to have a sufficient decrease in viscosity to 
permit compression but not enough to leak from the mould during compression.  This 
was done using melt rheology and the results presented in figure 2A and B. 
 
The optimum melt viscosity for melt compression moulding is between 2800 and 
4000Pa.S [42-43].  Figure 2A demonstrates that Kollidon® SR required a 
temperature of 180ºC in order to achieve an optimum melt viscosity.  Therefore, we 
investigated the effect of a adding a plasticiser (Kolliphor® P188) on the melt 
viscosity of the Kollidon SR and found that increasing the amount of plasticiser 
decreased the temperature required to achieve the optimum melt viscosity (Figure 
2A).  However, the addition of too much plasticiser can have a detrimental effect on 
the physical characteristics (hardness, friability and drug release) of a tablet [44].  
Therefore, it was decided to use 10% plasticiser and a processing temperature of 
160oC to manufacture the Kollidon® SR layers as this provided a melt viscosity 
within the optimum range (Figure 2A).  
  
Kollidon® VA had an optimum melt viscosity at temperatures ranging from 150ºC to 
180ºC, while the addition of a plasticiser had limited influence on its melt viscosity 
(Figure 2B) when compared to Kollidon® SR (Figure 2A).  However, it was decided to 
use 5% plasticiser and a processing temperature of 150ºC as the addition of a small 
quantity of plasticiser can reduce the brittleness of the tablets and improve their 
hardness and friability [44]. 
3.2 Characterisation of the multi-layered tablets 
Each layer was formulated and developed to have a specific drug content depending 
on the drug, type of release and the multi-layered tablet in which they were to be 
used.  The immediate release ACY and LNG layers were formulated to contain 300 
and 2g respectively for all tablet configurations.  Both the immediate and sustained 
release DPV layers intended to be used in the three layered tablets were formulated 
to contain 400g, while those intended to be used in the four layered tablets, which 
contain both an immediate and sustained release DPV layer, were formulated to 
contain either 200 or 400g depending on the tablet.  The content uniformity data for 
each of the layers is presented in Table 2 and demonstrates that all of the layers 
contained drug contents similar to their theoretical values (P > 0.05).  Furthermore, 
all of the layers meet the European Pharmacopeia 2.9.40 Uniformity of Dosage units 
acceptance value at level 1, accept for the 400g immediate release DAP layer, 
which did meet it at level 2 (Table 2). 
 
Major concerns with multi-layered tablets include poor mechanical properties, such 
as a high friability rate or low hardness, due to weaknesses at the joins between the 
layers [45].  However, the percent friability (Figure 4A and B), which is a method to 
  
determine the physical strength of tablets upon exposure to mechanical shock or 
agitation, for all of the multi-layered tablets was less than the limit of 1.0%.  
Furthermore, all of the multi-layered tablets had a hardness value significantly 
greater (p < 0.05) than 40N (Figure 4C) which is deemed acceptable for vaginal 
tablets.  
3.3 In vitro release 
The multi-layered tablet technology could be used to provide an MPT strategy, were 
each layer would contain either a HIV microbicide, a contraceptive or a drug to 
reduce other STIs such as HSV, with each layer designed to provide either 
immediate or sustained release of any or all of the actives.  In this study, a range of 
multi-layered tablets were developed that contained either 400 or 600g of DPV, 
300g of ACY and 2g of LNG.  Figure 5A and B show the release profile for a multi-
layered tablet that consists of three immediate release layers, one containing 400g 
of DPV, one containing 300g of ACY and the other containing 2g of LNG.  All 
layers released their total drug content within 1 hour, while a multi-layered tablet 
consisting of two immediate release outside layers (one containing 300g of ACY 
and the other 2g of LNG) and a sustained release central layer (containing 400g 
of DPV) also released their ACY and LNG content within one hour while sustaining 
the release of DPV for up to 8 hours (Figures 5C and D). 
 
The release profile of a multi-layered vaginal tablets consisting of three immediate 
release layers and a sustained release layer is presented in Figure 6.  Figures 6A 
and B show the release profiles for tablets whose outer immediate release layers 
  
contain 300g of ACY and 2g of LNG, while the central immediate release layer 
contains 200g of DPV with the central sustained release layer also containing 
200g of DPV.  The release profiles demonstrate that the immediate release outer 
layers released their ACY and LNG content within one hour, while approximately 
263g of DPV was released within an hour due to a combination of both the 
immediate and sustained release DPV layers, with the sustained release layer 
continuing to release DPV for up to 8 hours.  The release profiles for a similar multi-
layered vaginal tablet, only this time the central immediate release layer contains 
400g of DPV, is shown in Figures 6C and D.  Like the previous tablet all of the ACY 
and LNG was released within the first hour.  However, there is a significantly greater 
release (p < 0.05) of DPV within the first hour (477g) due to the central immediate 
release layer containing twice as much DPV, while the sustained release layer 
continues to release DPV for up to 8 hours.  These types of tablets could be used to 
provide an immediate ‘burst’ of DPV from the immediate release layer, which would 
provide immediate protection from HIV infection, while the sustained release layer 
could be used to continually ‘top-up’ the DPV concentration in the vaginal mucosa 
potentially providing protection for the rest of the day. 
 
3.3 Enhanced degradation and stability study 
The co-formulation of different active pharmaceutical ingredients into the same tablet 
can result in enhanced destabilisation due to incompatibilities or interactions 
between the actives [46].  Figure 7A demonstrates that when stored individually 
under conditions designed to enhance degradation all three actives maintain 100% 
stability after one month and after three months the ACY, DPV and LNG have 
  
maintained 95, 93 and 90% stability respectively.  However, when they are stored in 
combination (Figure 7B) their rate of degradation is significantly enhanced  (p < 0.05) 
and within one month the ACY, DPV and LNG have only maintained 92, 90 and 85% 
respectively of their stability.  Furthermore, after three months their stability has 
reduced further to 79, 76 and 75% (Figure 7B).  The rate of degradation for the 
actives in the multi-layered vaginal tablets containing three layers (Figures 7C and 
D) was significantly less (p < 0.05) that that for the combination control (Figure 7B).  
After three months the stability of ACY, DPV and LNG is 93, 90 and 88% 
respectively for the multi-layered vaginal tablet containing three immediate release 
layers and 91, 94 and 86% for the tablet containing a central sustained release layer. 
A similar trend occurs with the multi-layered vaginal tablets containing four layers 
(Figures 7E and F), with the ACY and DPV having approximately 91% stability and 
the LNG having approximately 88% stability after three months.  This is due to the 
drugs being formulated into separate layers, which means they do not come into 
contact with each other, thus the issue of incompatibilities or interactions is removed.     
  
  
4. Conclusion 
DPV, ACY and LNG were formulated into a range of three and four layered multi-
layered vaginal tablets designed to provide independent release of each of the 
actives.  The three layered vaginal tablets were designed to provide either immediate 
release of all three actives or immediate release of the ACY and LNG only, with DPV 
being released in a sustained fashion for up to eight hours.  The four layered vaginal 
tablets were designed to again provide immediate release of both ACY and LNG 
from the two immediate release outside layers, while an immediate release central 
layer provided a burst of DPV within the first hour of release and a central sustained 
release layer provided sustained release of DPV for the next 7 hours.  Furthermore, 
all of the tablets pass fortest for friability and met the European Pharmacopeia 
acceptance value for uniformity of dosage at level 1 and 2, while their hardness 
values were significantly greater than 40N, which is the unofficial acceptable lower 
limit for vaginal tablets.  This platform multi-layered tablet technology has the 
potential for providing women with protection from both HIV and HSV infection as 
well as unwanted pregnancy using a single dosage form.  The number of layers 
could be increased allowing for the delivery of more than one microbicide.   
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Figure captions 
 
Figure 1: Schematic of the various multi-layered DPV, ACY and LNG MPT vaginal 
tablets. 
 
Figure 2: Melt rheology of Kollidon® SR (A) and Kollidon® VA (B) from 200 to 120ºC 
with varying loadings (0 to 25%) of the plasticiser Kolliphor® P188.  The dashed lines 
are the optimum viscosity range. 
 
Figure 3: Melt rheology of Kollidon® SR (A) and Kollidon® VA (B) from 200 to 140ºC 
with varying loadings (0 to 1%) of DPV and Kollidon® VA with varying loadings (0 to 
1%) of ACY (C) and LNG (D).  The dashed lines are the optimum viscosity range. 
 
Figure 4: Percent friability of the multi-layered vaginal tablets containing either three 
(A) or four (B) layers.  The average (n = 10) tablet hardness and standard deviation 
(C) for all of the multi-layered vaginal tablets. 
 
Figure 5: The in vitro release of Dapivirine, Acyclovir (A) and Levonorgestrel (B) 
from a multi-layered vaginal tablet with three immediate release layers. The in vitro 
release of Dapivirine and Acyclovir (C) and Levonorgestrel (D) from a multi-layered 
vaginal tablet with two immediate release outside layers (300g Acyclovir and 2g 
Levonorgestrel) and a sustained release central layer (400g Dapivirine). 
 
Figure 6: The in vitro release of Dapivirine, Acyclovir (A) and Levonorgestrel (B) 
from a multi-layered vaginal tablet with two immediate release outside layers (300g 
Acyclovir and 2g Levonorgestrel) an immediate release central layer (200g 
Dapivirine) and a sustained release central layer (200g Dapivirine). The in vitro 
release of Dapivirine, Acyclovir (C) and Levonorgestrel (D) from a multi-layered 
vaginal tablet with two immediate release outside layers (300g Acyclovir and 2g 
Levonorgestrel) an immediate release central layer (400g DPV) and a sustained 
release central layer (200g Dapivirine). 
 
Figure 7:  Percent stability of DPV, ACY and LNG stored at 80oC in open containers 
in the individual control (A), combination control (B), multi-layered vaginal tablets 
with 3 layers (C and D) and multi-layered vaginal tablets with four layers (E and F).  
 
Table captions 
 
Table1:  Mobile phase composition for the gradient HPLC method  
Table 2: Theoretical and actual drug content for each of the individual tablet layers. 
  
  
Time 
(Min) 
Mobile Phase A 
(%) 
Mobile Phase B 
(%) 
0 40 60 
3 40 60 
10 30 70 
15 30 70 
25 40 60 
 
  
  
Drug Dapivirine Acyclovir Levonorgestrel 
Release Immediate Sustained Immediate Immediate 
Theoretical (g) 400 200 400 200 300 2 
Actual (g) 
(Std Dev) 
403.2 
(6.3) 
201.9 
(2.9) 
402.7 
(5.7) 
202.1 
(3.1) 
301.9 
(2.5) 
2.1 
(0.19) 
Acceptance 
Value 
15.4 7.0 13.7 7.4 6.0 5.5 
 
 
  
  Figure 1 
 
 
 
 
 
                       DPV IR = Dapivirine Immediate Release 
                       DPV SR = Dapivirine Sustained Release 
                       ACY IR = Acyclovir Immediate Release 
                       LNG IR = Levonorgestrel Immediate Release 
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